Clinical Trial Update: A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic study of PEP005 (Ingenol Mebutate) Gel 0.05% in actinic keratosis. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• PEP005 (Ingenol Mebutate) Gel 0.05% (Ingenol Mebutate)

Snippet

Sponsor: Peplin | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED | Results posted: 2012-05-28